Document:

Exhibit

Exhibit 10.2

ADVISOR AGREEMENT
THIS AGREEMENT entered into this 31st day of January, 2019 
B E T W E E N:
KINGSWAY AMERICA INC.
(“Kingsway”)
and
SEQUOIA FINANCIAL LLC

(“Advisor”)

WHEREAS Hassan R. Baqar (“Baqar”) has the been the Vice President of Finance for Kingsway and Kingsway Financial Services Inc. (“KFS”) since January 1, 2010;

AND WHEREAS Kingsway will be eliminating his position effective as of January 31, 2019 (the “Effective Date”);

AND WHEREAS Kingsway and Baqar have entered into an Employment Separation Agreement and Release dated January 31, 2019 (the “Separation Agreement”);

AND WHEREAS Kingsway and its affiliates wish to retain the services of Baqar through Advisor for a transitional period, in light of Baqar’s considerable and valuable skills, experience and institutional knowledge;

AND WHEREAS Kingsway wishes to enter into this Advisor Agreement (the “Agreement”) with Advisor for an initial term of twelve months from the date of the Agreement, and Advisor wishes to act as an advisor to Kingsway for such initial term;

AND WHEREAS it is the intention of Kingsway and Advisor (the “Parties”) to establish an independent contractor relationship for all purposes and not continue an employee and employer relationship;

ACCORDINGLY, for good and valuable consideration the Parties enter into this Agreement whereby Advisor will provide the advisory services to Kingsway under the following terms:

ADVISORY SERVICES
		
	1.
	Kingsway hereby retains the advisory services of Advisor in respect of the matters set out in Appendix “A” to this Agreement (the “Services”).

		
	2.
	Advisor agrees that it will devote the necessary time and energy to ensure the Services are carried out to the reasonable satisfaction of Kingsway as set forth in this Agreement. 

FEES
		
	3.
	Immediately following the Effective Date, Advisor shall receive a base consulting fee of USD $3,333.33 per month, payable in arrears. The first payment will be due on March 1, 2019 and additional payments will be due on the same day of each month thereafter. Advisor shall also be entitled to the reimbursement of reasonable, documented, out of pocket expenses incurred by it in connection with the provision of the Services.

Exhibit 10.2

		
	4.
	After the end of the Term (as defined below) of this Agreement, any subsequent provision of, and compensation for, Services shall be subject to negotiation between the Parties. 

		
	5.
	Kingsway shall make its staff reasonably available to Advisor in support of provision of the Services for the Term of this Agreement. 

TERM
		
	6.
	The term of this Agreement shall commence on the Effective Date, for an initial term of twelve (12) months after the Effective Date (the “Initial Term”), unless terminated earlier or extended as provided by this Agreement. The Parties may mutually agree to extend the Initial Term or any renewal term of this Agreement for subsequent three (3) month terms (the term of this Agreement, as may be extended, the “Term”).  For greater certainty, the Term will lapse unextended at the end of such Term unless the Parties mutually agree on the subsequent three (3) month extension. 

		
	7.
	Notwithstanding Section 6 above, Kingsway or Advisor may terminate this Agreement upon a material breach by the other party, which breach is not cured within ten (10) days of written notice.  If the Agreement is terminated by Kingsway for any material breach by the Advisor, no further base consulting fee payments shall be due Advisor attributable to any period after the termination date.  If the Agreement is terminated by Advisor for any material breach by Kingsway, Advisor will render no further Services to Kingsway for any period after the termination date.

		
	8.
	Sections 12, 13, 16, General and Arbitration shall survive any termination or expiration of this Agreement.

PROVISION OF SERVICES
		
	9.
	Except as may be otherwise set forth in this Agreement, Advisor agrees that Kingsway shall not be responsible for providing an office, a vehicle, equipment, tools, licencing fees, or insurance coverage in order for Advisor to provide Services.  Kingsway agrees to allow Baqar to take ownership of the Kingsway laptop, monitors, scanner and printer currently assigned to Baqar during his employment.

		
	10.
	Kingsway agrees that Advisor shall determine its schedule and methodology to ensure that the Services rendered are completed within any reasonable project timetable established by Kingsway after consultation with Baqar.

		
	11.
	It is agreed that Advisor shall act as an independent contractor in the provision of all Services under this Agreement.  Accordingly, Advisor shall bear all liability that results from the provision of Services under this Agreement, including, but not limited to, remittances for any personal or corporate taxes, payroll taxes, insurance premiums or any other duties, levies or taxes.  For greater certainty, the Parties agree that nothing in this Agreement creates an employer and employee relationship between the Parties. 

		
	12.
	Advisor agrees to indemnify and save harmless Kingsway from any personal taxes, payroll withholding taxes, FICA, insurance premiums or any other duties, levies or taxes associated with any payment to Advisor under this Agreement.

NON-EXCLUSIVITY
		
	13.
	Kingsway acknowledges and agrees that Advisor’s provision of the Services hereunder is non-exclusive and Advisor/Baqar shall be entitled to enter into contracts for service or employment with other entities from time to time.

CONFIDENTIALITY
		
	14.
	Advisor and Baqar agree that they will not retain, use, misuse or disclose, directly or indirectly, any of Kingsway’s Confidential Information.  Advisor and Baqar understand and agree that for purposes of this Agreement, “Confidential Information” includes all confidential information and trade secrets of Kingsway and its parent company, subsidiaries and affiliates to which Baqar had access during his employment, all trade secrets and other information furnished by Kingsway to Baqar and all information to which Baqar gained access during his employment relationship with Kingsway which is either non-public,  confidential or proprietary in nature, whether such information is legally privileged or the property of Kingsway (or its parent company, subsidiaries or affiliates). Confidential Information does not include Baqar’s general knowledge and know-how that is not proprietary to Kingsway, including, but not limited to, utilization of NOL’s to capitalize real estate transactions, and such information concerning insurance backed securities.  Confidential Information also does not include: (a) information that was available to the general public at the time it was disclosed or which through no act or omission of Advisor or Baqar, becomes publicly available; (b) information that Advisor or Baqar rightfully possessed independent of any obligation of confidentiality; (c) information that Advisor or Baqar rightfully receives without obligation of confidentiality from any third-party; or (d) information Advisor or Baqar develops 

Exhibit 10.2

independently without using the Confidential Information.  Advisor and Baqar recognize that such Confidential Information is a unique asset of Kingsway, developed and perfected over a considerable time and at substantial expense to Kingsway and the disclosure of which may cause injury, loss of profits and loss of goodwill to Kingsway or its parent company, subsidiaries or affiliates.  
		
	15.
	Advisor and Baqar understand that the nature of Advisor’s advisory role with Kingsway and its subsidiaries may give Baqar access to and knowledge of Confidential Information. Advisor and Baqar further understand and acknowledge that Kingsway's and its parent and subsidiaries' ability to protect their respective Confidential Information is of great competitive importance and commercial value to Kingsway and its parent and subsidiaries, and that improper use or disclosure by Advisor or Baqar may result in unfair or unlawful competitive activity.

NO BREACH OF OTHER OBLIGATIONS
		
	16.
	Baqar and Advisor acknowledge and represent to Kingsway that:

		
	(a)
	The performance of the Services for Kingsway by Advisor and any of his employees and/or agents shall not breach any non-competition agreement, non-solicitation agreement or any agreement to keep confidential the proprietary information of any present or prior client, employer or proprietor of Baqar, Advisor or any third party.

		
	(b)
	Baqar and Advisor also acknowledge and represent to Kingsway that Baqar and Advisor shall not use in the performance of the Services any confidential materials or documents of any third party.

		
	(c)
	Baqar and Advisor further acknowledge and represent that they are not a party to any agreement or obligation with any third party, which conflicts with any obligations of Baqar and Advisor under this Agreement.

GENERAL
		
	17.
	Each of the Parties represents and warrants: (a) it/he has the power, capacity and authority to execute, deliver and carry out the terms and provisions of this Agreement and to consummate the transactions contemplated hereby; and (b) this Agreement has been duly authorized, executed and delivered by it/him and constitutes a legal, valid and binding obligation enforceable against it in accordance with its terms.  

		
	18.
	This Agreement shall be governed by and construed in accordance with the laws of Illinois, without reference to its conflict of laws principles.

		
	19.
	The invalidity or unenforceability of any provision of the Agreement shall not affect the validity or enforceability of any other provision in this Agreement. Any court is expressly authorized to modify any unenforceable provision of this Agreement instead of severing the unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting any or all of the offending provision, adding additional language to the provision, or making any other modifications it deems warranted to carry out the intent and purpose of the Agreement.

		
	20.
	This Agreement, including any of the rights, duties or obligations herein, is not assignable or transferable by Kingsway or Advisor without the prior written consent of the other party. Any attempt to assign any of the rights, duties or obligations in this Agreement without such written consent is void.

		
	21.
	Apart from Kingsway and Advisor, no other person shall have any rights under this Agreement.

		
	22.
	Advisor shall ensure that only Baqar shall provide the Services to Kingsway, unless Kingsway provides written consent to allow another employee or agent of Advisor to provide it services on behalf of Advisor.

		
	23.
	There shall be no waiver of breach of any term or condition of this Agreement unless the waiver is in writing signed by the party who has not committed the breach.

		
	24.
	Baqar and Advisor agree that this Agreement represents a new relationship with Kingsway and not a continuation of any pre-existing relationship.

		
	25.
	This Agreement, including Appendix “A,” and the Separation Agreement contain the entire understanding among Kingsway, Advisor and Baqar with respect to the subject matter hereof and thereof, there are no restrictions, agreements, promises, representations, warranties, covenants or other undertakings other than those expressly set forth in this Agreement and the Separation Agreement that pertain to the subject matter of this Agreement and the Separation Agreement; provided, however, that this Agreement does not supersede other agreements between the Parties relating to other matters. This Agreement may be amended only by a written instrument duly executed by all of the Parties or their respective successors or assigns.

		
	26.
	Advisor acknowledges that it has had the opportunity to receive independent legal advice or such other advice as it has deemed necessary in relation to this Agreement. Advisor further acknowledges that Advisor understands its rights and obligations under this Agreement, is voluntarily signing this Agreement, and accepts the terms of this Agreement.

Exhibit 10.2

ARBITRATION
		
	27.
	The Parties agree that any dispute, controversy, or claim arising out of or related to in any way to this Agreement, or any breach of this Agreement or the Separation Agreement, shall be submitted to and decided by binding arbitration in Chicago, Illinois.  Arbitration shall be administered under the laws of the American Arbitration Association (AAA) in accordance with the AAA’s Employment Arbitration Rules in effect at the time the arbitration is commenced.  The AAA’s rules are also available online at www.adr.org.  Discovery in any arbitration proceeding shall be conducted according to the AAA’s Employment Arbitration Rules.  To the extent not provided for in the AAA’s Employment Arbitration Rules, the Arbitrator has the power to order discovery upon a showing that discovery is necessary for a party to have a fair opportunity to present a claim or defense.

		
	28.
	This agreement to arbitrate covers all grievances, disputes, claims, or causes of action that otherwise could be brought in a federal, state, or local court or agency under applicable federal, state, or local laws,  including claims Advisor may have against Kingsway or against its officers, directors, supervisors, managers, employees, or agents in their capacity as such or otherwise, or that Kingsway may have against Advisor.  The claims covered by this agreement to arbitrate include, but are not limited to, claims for breach of any contract or covenant (express or implied), tort claims, claims for wages, or other compensation due, claims for wrongful termination (constructive or actual), claims for discrimination or harassment (including, but not limited to, harassment or discrimination based on race, age, color, sex, gender, national origin, alienage or citizenship status, ancestry, creed, religion, marital status, partnership status, military status, unfavorable discharge from military service, order of protection status,  predisposing genetic characteristics, medical condition, psychological condition, mental condition, criminal accusations and convictions, arrest record, expunged or sealed convictions, disability, pregnancy, sexual orientation, or any other trait or characteristic protected by federal, state, or local law), and claims for violation of any federal, state, local, or other governmental law, statute, regulation, or ordinance relating to the matters set forth in this Agreement.

		
	29.
	Parties expressly intend and agree that: (a) class action and representative action procedures shall not be asserted, nor will they apply, in any arbitration; (b) each will not assert class action or representative action claims against the other in arbitration or otherwise; and (c) Parties shall only submit their own, individual claims in arbitration and will not seek to represent the interests of any other person.  Further, Parties expressly intend and agree that any claims by Advisor and/or Baqar will not be joined, consolidated, or heard together with claims of any other employee of Kingsway.

		
	30.
	Any arbitral award determination shall be final and binding upon the Parties.  Judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof.

		
	31.
	If any provision of this agreement to arbitrate is adjudged to be void or otherwise unenforceable, in whole or in part, the void or unenforceable provision shall be severed and such adjudication shall not affect the validity of the remainder of this agreement to arbitrate.

		
	32.
	Any and all notices or other communications hereunder shall be in writing and shall be deemed properly served (i) on the date sent if transmitted by hand delivery with receipt therefore, (ii) on the date of transmittal if sent by email if sent on a business day, if not, on the next succeeding business day, (iii) one business day after the notice is deposited with an overnight courier, or (iv) three (3) days after being sent by registered or certified mail, return receipt requested, first class postage prepaid, addressed as follows (or to such new address as the addressee of such a communication may have notified the sender thereof):

To Kingsway:                Kingsway America Inc.
150 Pierce Road, Suite 600
Itasca, IL  60143
Attn:    William A. Hickey, Jr.
Phone:    847-871-6416
Email:    whickey@kingswayfinancial.com

    

Exhibit 10.2

		
	To Advisor:
	Attention: Hassan R. Baqar

Sequoia Financial LLC
425 Jason Lane, Schaumburg, IL 60173
Phone:    847-791-6817
Email:    razabaqar@hotmail.com
		
	33.
	All costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses.

[Signature page follows.]
[Signature Page to Advisor Agreement]

DATED at Itasca, IL this 31st day of January, 2019.
	
					
	 
	 
	KINGSWAY AMERICA INC.

	 
	 
	Per:
	 

	 
	 
	 
	Name:  

	 
	 
	 
	Title:  

DATED at Itasca, IL this 31st day of January, 2019.
	
			
	Witness
	 

	Name:  Hassan R. Baqar
            Managing Member
            Sequoia Financial LLC

    

Exhibit 10.2

APPENDIX “A”

Services Summary:    Unless specifically set forth otherwise below, Advisor shall be responsible for providing the following Services to Kingsway and its affiliates in exchange for payment of the base consulting fee as set forth in the attached Agreement: 
		
	1.
	Risk mitigation - cooperate with Kingsway in the truthful and honest investigation, prosecution and/or defense of any claim in which Kingsway or any of its subsidiaries or KFS may have an interest, which may include, without limitation, making himself available on a reasonable basis to participate in any legal or regulatory proceeding involving any of such persons, allowing himself to be interviewed by representatives of Kingsway, participating as requested in interviews and/or preparation by any of such persons of other witnesses, protecting the applicable legal privileges of such persons, appearing for depositions and testimony without requiring a subpoena, and producing and/or providing any documents or names of other persons with relevant information.  

		
	2.
	Value maximization and monetization of investments - assist Kingsway with the review, evaluation, management and monetization of certain investments within the knowledge of Baqar during his tenure with Kingsway and KFS.

		
	3.
	Audit assistance - engage as requested with Kingsway’s auditor, RSM, to facilitate the completion of the 2018 audit.

		
	4.
	Scope - Advisor will generally make himself available during the Term up to a cumulative number of hours intended to be in the proportion that the fees paid to Advisor are to the base salary that Baqar would have been paid during the same period.  Advisor, in his capacity as an independent contractor, will have discretion over when the hours are worked.Exhibit 10.1

 

*Portions of this exhibit marked [*] are requested to be
treated confidentially.

 

Patent and Technology License
Agreement

 

This Patent and Technology License Agreement
(“Agreement”) is made by and between The Board of Regents (“Board”) of The University of
Texas System (“System”), an agency of the State of Texas, whose address is 210 West 7th Street, Austin, Texas
78701, on behalf of The University of Texas M. D. Anderson Cancer Center (“MD Anderson”), a member institution
of System, and Citius Pharmaceuticals, Inc., a Nevada corporation having a principal place of business located at 11 Commerce Drive,
First Floor, Cranford, New Jersey 07016 (“Licensee”).

 

Recitals

 

		A.	Board owns Licensed Subject Matter (defined below).

 

		B.	Board, through MD Anderson, has determined that development and commercialization of the Licensed
Subject Matter is in the public’s best interest and is consistent with Board’s educational and research missions and
goals.

 

		C.	Board desires to have the Licensed Subject Matter developed and commercialized for the benefit
of Licensee, the inventors, Board, System, MD Anderson, and the public.

 

		D.	Licensee desires to secure a license to practice the Licensed Subject Matter.

 

NOW, THEREFORE, in consideration of the
mutual covenants and promises herein contained, the parties agree as follows:

 

 I. Effective Date

 

	1.1	This Agreement is effective as of the date fully executed by all parties (“Effective Date”).

 

 II. Definitions

 

As used in this Agreement, the
following terms have the meanings indicated:

 

		2.1	Affiliate
                                         means any business entity which, before or after the Effective Date, directly or
                                         indirectly through one (1) or more intermediaries controls, is controlled by or is under
                                         common control with Licensee. For purposes of this definition, a business entity shall
                                         be deemed to “control” another business entity if it (a) owns, directly or
                                         indirectly, beneficially or legally, at least fifty percent (50%) of the outstanding
                                         voting securities or capital stock of such other business entity, or has other comparable
                                         ownership interest with respect to any business entity other than a corporation, or (b)
                                         has the power, whether pursuant to contract, ownership of securities or otherwise, to
                                         direct the management and policies of the business entity.

 

     

     

    

 

		2.2	Combination
                                         Product means any product comprised of a combination of (i) a Licensed Product and
                                         (ii) any active ingredient(s), device(s), delivery system(s) or other technology(ies)
                                         for which rights are not included in the license granted under this Agreement but, with
                                         respect to the item(s) in (ii), which may each or collectively form the basis for a separately
                                         saleable product (an “Independent Subproduct”).

 

		2.3	Control
                                         including the correlative terms “Controls,” “Controlled by,”
                                         and “under common Control with,” means (a) the possession, directly or indirectly,
                                         of the power to direct or cause the direction of the management or policies (whether
                                         through ownership of securities or any partnership or other ownership interest, by contract
                                         or otherwise) of a Person, or (b) the ownership, directly or indirectly, of more than
                                         fifty percent (50%) of the outstanding securities or other ownership interest of such
                                         Person.

 

		2.4	Change
                                         of Control means any of the following, pursuant to any transaction or series of related
                                         transactions occurring on or after the Effective Date:

 

		(a)	any
                                         person, corporation, partnership, syndicate, trust, estate or other Group (as defined
                                         in Section 13(d) of the Securities Exchange Act of 1934 (the “Exchange Act”)),
                                         acting with a view to the acquisition, holding or disposition of securities or ownership
                                         interests of Licensee, (i) becomes, directly or indirectly through one or more series
                                         of transactions, the beneficial owner, as defined in Rule 13d-3 under the Exchange Act
                                         (“Beneficial Owner”), of securities or other ownership interests of
                                         Licensee representing more than fifty percent (50%) of the voting power of all outstanding
                                         securities or other ownership interests of Licensee having the right under ordinary circumstances
                                         to vote at an election of the Board of Directors or other governing body of such Licensee
                                         (the “Licensee Voting Securities”), or (ii) becomes in direct or indirect
                                         Control of the Licensee; provided, however, that the sale by Licensee of shares of its
                                         capital stock to investors in bona fide equity financing transactions are not a Change
                                         of Control for purposes of this Section 2.4(a), but only to the extent that existing
                                         stockholders of Licensee owning, in the aggregate, ninety-five percent (95.0%) of the
                                         issued and outstanding securities of the Licensee do not receive any proceeds from, related
                                         to, or otherwise in connection with such bona fide equity financing transactions;

 

    2

     

    

 

		(b)	the consummation of a reorganization, merger, consolidation, or similar transaction involving Licensee,
unless,

 

		(i)	the stockholders or other equity owners of Licensee immediately prior to the reorganization, merger,
consolidation, or similar transaction involving Licensee, beneficially own, in the aggregate, immediately after the reorganization,
merger, consolidation, or similar transaction, shares or other ownership interests entitling such stockholders to beneficially
own, in the aggregate, fifty percent (50.0%) or more of the voting power of the outstanding securities or other ownership interests
of the corporation or entity resulting from or surviving such reorganization, merger, consolidation, or similar transaction, or
having the right under ordinary circumstances to vote at an election of the board of directors or other governing body of such
resulting corporation or entity in substantially the same proportions as their ownership, immediately prior to such reorganization,
merger, consolidation, or similar transaction, of the Licensee Voting Securities; or

 

		(ii)	the individuals serving as members of the Board of Directors or other governing body of Licensee,
immediately prior to the reorganization, merger, consolidation, or similar transaction, constitute, immediately after such reorganization,
merger, consolidation, or similar transaction, all of the board of directors or other governing body of the corporation or other
entity surviving or resulting from such reorganization, merger, consolidation, or similar transaction;

 

		(c)	the consummation of a sale or other disposition of all or a material portion of the assets of Licensee
or one of Licensee’s Affiliates, in either case including the Licensed Subject Matter, and including without limitation,
an assignment of this Agreement to a party other than an Affiliate of Licensee (“Assignment”);

 

		(d)	an initial public offering by the Licensee or by one of the Licensee’s Affiliates provided
that such Affiliate is a sublicensee under this Agreement or has been extended rights by Licensee under this Agreement; or

 

		(e)	the
                                         approval of the stockholders or other equity owners of Licensee or one of Licensee’s
                                         Affiliates of a plan of complete liquidation of the Licensee or such Licensee Affiliate;
                                         provided, however, that a liquidation in which none of the common and the preferred stockholders
                                         or other equity owners of the Licensee or Licensee’s Affiliates, as applicable,
                                         has received any distribution as a result of the liquidation preference of Licensee is
                                         not a Change of Control for purposes of this Section 2.4(d).

 

		2.5	European Union means the countries comprising the European Union as of the Effective Date.

 

		2.6	Independent Subproduct shall have the meaning set forth in Section 2.2.

 

		2.7	Licensed Field means any and all uses and applications relating to breast implants, including
without limitation coatings and expanders used for either reconstructive or cosmetic purposes. The Licensed Field excludes any
use or application other than with respect to breast implants.

 

    3

     

    

 

		2.8	Licensed Products means any material, composition, product, or service comprising, using,
or made using any portion of Licensed Subject Matter.

 

		2.9	Licensed Subject Matter means (a) Patent Rights, (b) Technology Rights, and/or (c) inventions
covered by Patent Rights and/or Technology Rights.

 

		2.10	Licensed Territory means worldwide.

 

		2.11	Net Sales means the gross revenues invoiced by, or on behalf of Licensee or its Affiliate(s)
from a Sale less the following items, to the extent that such items have not been previously accounted for in the invoiced amount:

 

		(a)	trade, quantity, and other discounts actually granted;

		(b)	rebates, credits, and chargeback payments actually granted to managed health care organizations,
wholesalers, or to federal, state/provincial, local and other governments, including their agencies, purchasers, and/or reimbursers;

		(c)	sales and/or use taxes actually paid;

		(d)	import or export duties, tariffs, or taxes actually paid;

		(e)	transportation and insurance charges actually paid or allowed;

		(f)	allowances, rebates, credits, or refunds for returned or defective goods (not exceeding the original
billing or invoice amount);

 

all as recorded by Licensee in
its official books and records in accordance with applicable generally accepted accounting practices and consistent with their
financial statements and/or, if applicable, regulatory filings with the United States Securities and Exchange Commission.

 

If a Licensed Product is sold
as part of a Combination Product, Net Sales shall be calculated by multiplying Net Sales for such Combination Product by the fraction
A/(A+B) (“Reduction Factor”) where A is the invoice price of the Licensed Product when sold separately, and B is the
aggregate invoice price of the Independent Subproduct(s) in the combination when sold separately. If either the Licensed Product
or the Independent Subproduct(s) is(are) not at that time sold separately, then the allocation of Net Sales shall be commercially
reasonable and determined by good faith negotiation between MD Anderson and Licensee, based on the relative value of the Licensed
Product and Independent Subproduct(s), consistent with the formula provided above but, in such case, Licensee shall have no right
to sell the combination product until MD Anderson and Licensee have reached a written agreement with respect to the royalty rate
to be paid by Licensee with respect to such combination product. Notwithstanding the foregoing, in no event shall the Reduction
Factor for Net Sales for the Combination Product in such written agreement be less than fifty percent (50%).

 

    4

     

    

 

		2.12	Patent Expenses means documented out-of-pocket expenses incurred by MD Anderson in preparing
(including conducting prior art searches, if any), filing, prosecuting (including post-grant proceedings), defending, enforcing
and maintaining patent applications and patents under Patent Rights.

 

		2.13	Patent Rights means the Board’s rights in:

 

		(a)	the patents and patent applications listed in Exhibit I to this Agreement;

 

		(b)	all non-provisional patent applications that claim priority to, or common priority with, any of
the provisional applications listed in subpart (a) provided that the claims of such non-provisional applications are entitled to
claim priority to such provisional applications;

 

		(c)	all divisionals, continuations and continuations-in-part of the non-provisional patent applications
identified in (a) and (b), above provided that the claims of such continuations-in-part are entitled to claim priority to at least
one of the patent applications identified in (a) or (b), above;

 

		(d)	all reissues, reexaminations, extensions, supplementary protection certificates, and foreign counterparts
of any of the patents or patent applications identified in (a), (b) or (c), above; and

 

		(e)	any patents that issue with respect to any of the patent applications listed in (a), (b), (c) or
(d), above.

 

		2.14	For
                                         purposes of Section 2.3, Person means any individual, partnership, joint venture,
                                         limited liability company, corporation, firm, trust, association, unincorporated organization,
                                         governmental authority or agency, or any form of legal entity under applicable laws not
                                         specifically listed herein.

 

		2.15	Regulatory
                                         Approval means the approval or clearance needed in a particular country or jurisdiction
                                         by a Regulatory Authority to begin marketing and/or sale of a Licensed Product in such
                                         country or jurisdiction, which shall include, if applicable, pricing approvals.

 

		2.16	Regulatory
                                         Authority means any applicable governmental regulatory authority involved in granting
                                         approvals for marketing and/or sale of a Licensed Product, including without limitation,
                                         the United States Food and Drug Administration (“FDA”).

 

		2.17	Sale,
                                         Sell, or Sold means the transfer or disposition of a Licensed Product for
                                         value by Licensee or any Affiliate of Licensee; provided, however, that the following
                                         transfers and dispositions of a Licensed Product for value shall not be included in Sales:

 

		(a)	Any transfer to a Royalty Free Practitioner. As used herein, “Royalty-Free Practitioner”
means MD Anderson and the following individuals: Issam Raad, M.D.; George Viola, M.D.; and Jesse Selber, M.D. (“Physician
Inventors”), and any partner or associate who practices medicine with one or more of the Physician Inventors, but with
respect to such partner or associate, only for such time as he/she is engaged in a bona fide medical practice with one or more
of the Physician Inventors;

 

    5

     

    

 

		(b)	Any transfer to Licensee or any Affiliate of Licensee, unless such Licensee or Affiliate acquires
such Licensed Product for end use; and

 

		(c)	Any transfer of Licensed Products provided for clinical trials, research purposes, or charitable
or compassionate use purposes for consideration at or below cost.

 

		2.18	Technology Rights means Board’s rights in technical information, know-how, processes,
procedures, compositions, devices, methods, formulas, protocols, techniques, designs, drawings or data created at MD Anderson before
the Effective Date by the inventor(s) listed in Exhibit I while employed at MD Anderson and within the Licensed Field which (a)
are not covered by Patent Rights, (b) facilitate the practice, development, manufacture, use, and/or selling of invention(s) claimed
in the patents and/or patent applications listed in the definition of Patent Rights, whether outstanding, expired or abandoned;
and (c) have no obligations or encumbrances in favor of or benefitting any third party and are not otherwise subject to contractual
or legal restrictions that would preclude a license to Licensee under this Agreement.

 

		2.19	Valid
                                         Claim means a claim of (a) an issued and unexpired patent included within the Patent
                                         Rights unless the claim has been held unenforceable or invalid by the final, un-reversed,
                                         and un-appealable decision of a court or other governmental body of competent jurisdiction,
                                         has been irretrievably abandoned or disclaimed, or has otherwise been finally admitted
                                         or finally determined by the relevant governmental authority to be invalid, un-patentable
                                         or unenforceable, whether through reissue, reexamination, disclaimer or otherwise, or
                                         (b) a pending patent application within the Patent Rights to the extent the claim continues
                                         to be prosecuted in good faith.

 

III. License

 

		3.1	Board, through MD Anderson, hereby grants to Licensee a royalty-bearing, exclusive license (with
no right to grant sublicenses) under Patent Rights to manufacture, have manufactured, use, import, offer to sell and/or sell Licensed
Products within Licensed Territory for use within Licensed Field.

 

		3.2	Board, through MD Anderson, hereby grants to Licensee a royalty-bearing, non-exclusive license
(with no right to grant sublicenses) under Technology Rights to manufacture, have manufactured, use, import, offer to sell and/or
sell Licensed Products within Licensed Territory for use within Licensed Field.

 

    6

     

    

 

		3.3	Licensee may extend the grants of Sections 3.1 and 3.2 to any Affiliate provided that such Affiliate
consents in writing to be bound by this Agreement to the same extent as Licensee; provided, however, that such Affiliate shall
not further extend or sublicense the grants of Sections 3.1 and 3.2 to another Affiliate or any other third-party. For the avoidance
of doubt, if Licensee extends such license grants to one of its Affiliates, as contemplated by this Section 3.3, such Affiliate
shall comply, and Licensee shall also be liable for each such Affiliate’s compliance, with all of the terms and conditions
of this Agreement. 

 

		3.4	The grants of this Article III are further subject to 13.2 and 13.3 hereinbelow, the payment by
Licensee to MD Anderson of all consideration as provided herein, and are further subject to the following rights retained by Board
and MD Anderson to:

 

		(a)	Publish the general scientific findings from research related to Licensed Subject Matter, subject
to the terms of Article X–Confidential Information and Publication; and

 

		(b)	Use Licensed Subject Matter for patient care at MD Anderson, non-commercial research, teaching,
and other academically-related purposes; and

 

		(c)	Transfer Licensed Subject Matter to academic or research institutions for non-commercial research
use.

 

		3.5	The parties hereby acknowledge and agree that any exercise by Licensee of the license grant set
forth in this Section 3.1 and/or Section 3.2 outside the scope of the Licensed Field shall be deemed a material breach of this
Agreement.

 

		3.6	Licensee, itself or through an Affiliate, shall use commercially reasonable efforts to make Licensed
Products commercially available in the Licensed Field within the Licensed Territory. The efforts of Licensee’s Affiliates
shall be deemed efforts of Licensee for the purpose of determining Licensee’s compliance with this Section 3.6. Without limiting
the foregoing, Licensee shall use commercially reasonable efforts to:

 

		(a)	maintain a bona fide, funded, ongoing and active research, development, manufacturing, regulatory,
marketing or sales program (all as commercially reasonable) to make Licensed Products commercially available in the Licensed Field
to the public as soon as commercially practicable within the Licensed Territory, and

 

    7

     

    

 

		(b)	achieve the following Diligence Milestone Events by the deadlines indicated:

 

	 	Table 3.6(b)
	 	Diligence Milestone Events	 	Deadlines
	 	1.  Submit a 510(k) application to the FDA	 	Not later than [*] months after the Effective Date
	 	2.  Receive Regulatory Approval from FDA	 	Not later than [*] months after the Effective Date
	 	3.  First Sale	 	Not later than [*] months after the Effective Date

 

In the event that the FDA determines
that Licensed Products must be approved via any process other than the 510(k) clearance process, and Licensee subsequently files
an appeal with the FDA seeking a reexamination or reclassification of the clearance or approval process necessary to Sell Licensed
Products, this Section 3.6(b) is automatically amended such that each deadline set forth in Table 3.6(b) is extended by the longer
of (i) [*], or (ii) for so long as such appeal is pending before the FDA, or (iii) in the event such appeal is unsuccessful, for
so long as Licensee is diligently pursuing judicial review thereof.

 

In the event that the FDA determines
that Licensed Products must be approved via the premarket approval (“PMA”) process rather than via the 510(k) clearance
process, this Section 3.6(b) is automatically amended such that Diligence Milestone Event 1 of Table 3.6(b) instead reads “Submit
a PMA application to the FDA,” and each deadline set forth in Table 3.6(b) is extended by [*].

 

In the event that the FDA makes
a final, unappealable decision that a New Drug Application (“NDA”) is required prior to Sale of any Licensed Products,
Licensee’s obligations to achieve the Diligence Milestones under this Section 3.6(b) are waived.

 

If the obligations under Sections
3.6(a) and 3.6(b) are not fulfilled, Board and/or MD Anderson may treat such failure as a breach in accordance with Section 12.3(c).

 

		(c)	Within thirty (30) calendar days following each anniversary of the Effective Date, Licensee will
deliver to MD Anderson a written progress report as to Licensee’s and its Affiliates’ efforts and accomplishments during
the preceding year in using commercially reasonable efforts to develop and/or commercialize, as applicable, the Licensed Subject
Matter in the Licensed Territory and Licensee’s development and/or commercialization plans, as applicable, for the upcoming year.

 

 

 

[*] Confidential treatment requested; certain information omitted
and filed separately with the SEC.

    8

     

    

 

IV. Consideration,
Payments and Reports

 

		4.1	In consideration of rights granted by Board to Licensee under this Agreement, Licensee agrees to
pay MD Anderson each of the following:

 

		(a)	All Patent Expenses incurred by or for MD Anderson after the Effective Date for so long as this
Agreement remains in effect; provided however, that if Board, System or MD Anderson licenses Patent Rights to a party other than
Licensee, then Licensee shall pay a pro rata share of the Patent Expenses incurred by MD Anderson based on the number of licenses
for the Patent Rights during the time each such Patent Expense is incurred. MD Anderson will invoice Licensee on a quarterly basis
after the Agreement is fully executed. The invoiced amounts will be due and payable by Licensee within thirty (30) calendar days
of invoice. Patent Expense payment delinquencies will be considered a payment default under Section 12.2(b); and

 

		(b)	A nonrefundable upfront license fee in the amount of $125,000.00. This fee will not reduce the
amount of any other payment provided for in this Article IV, and is due and payable within thirty (30) calendar days after the
Agreement has been fully executed by all parties. The obligation to timely pay the license upfront fee is not subject to any cure
period; and

 

		(c)	Until and ceasing upon the first Sale, nonrefundable annual maintenance fees (“Annual
Maintenance Fees”) in the amount of $30,000.00, increasing annually by $15,000.00 until an amount of $90,000.00 until
first Sale (for example, the Annual Maintenance Fees due for the second, and third, fourth, and fifth anniversaries of the Effective
Date would be $45,000.00, and $60,000.00, $75,000.00, and $90,000.00, respectively, assuming such Annual Maintenance Fee is otherwise
payable in accordance with the terms of this Agreement). Annual Maintenance Fees are due and payable (without invoice) within thirty
(30) calendar days of each anniversary of the Effective Date until the first Sale. The Annual Maintenance Fees will not reduce
the amount of any other payment provided for in this Article IV; and

 

    9

     

    

 

		(d)	A running tiered royalty on Net Sales of all Licensed Products in the Licensed Territory as set
forth in Table 4.1(d) will apply:

 

	 	Table 4.1(d)
	 	Aggregate Net Sales in any calendar year	 	 	Royalty Rate on Net Sales	 
	 	Net Sales up to and including $15 million	 	 	[*]%	 
	 	Net Sales greater than $15 million	 	 	[*]%	 

 

If neither a particular Licensed
Product nor the use thereof is covered by a Valid Claim in the United States at the time that such Licensed Product is Sold in
the United States, then for so long as there is no such Valid Claim during the Royalty Term in the United States, the Royalty Rate
on the Net Sales of such Licensed Product Sold in the United States shall be reduced by twenty-five percent (25%), such that the
rates set forth in Table 4.1(d) will be, respectively, [*]% and [*]%; and

 

		(e)	After the first Sale, minimum annual royalties (“Minimum Annual Royalties”)
of $100,000.00, increasing by $25,000.00 each year thereafter (for example, the Minimum Annual Royalties due for the second, third,
and fourth anniversaries of the Effective Date are $125,000.00, $150,000.00, and $175,000.00, respectively, etc.), due and payable
(without invoice) within thirty (30) calendar days of the first and subsequent anniversaries of the Effective Date which follows
the first Sale; provided, however, that in the event that there is less than a twelve (12) month period between the first Sale,
and the first anniversary of the Effective Date which follows the first Sale, then Licensee shall pay the following:

 

		(i)	the Annual Maintenance Fee due for that year multiplied by the fraction A/C, where A is the number
of months between the anniversary of the Effective Date preceding the first Sale and the first Sale, and C is twelve (12); and

 

		(ii)	the Minimum Annual Royalties multiplied by the fraction B/C, where B is the number of months between
the first Sale and the first anniversary of the Effective Date which follows the first Sale, C is twelve (12), and A + B = twelve
(12).

 

Running royalties accrued under
Section 4.1(d) and paid to MD Anderson during the one-year period preceding an anniversary of the Effective Date shall be credited
against the Minimum Annual Royalties due on that anniversary date; and

 

		(f)	The following one-time milestone payments:

 

	 	Table 4.1(f)
	 	Milestone Events for Licensed Products	 	Milestone Payment
	 	Regulatory Approval of a Licensed Product in the United States	 	$[*] 

	 	Regulatory Approval of a Licensed Product in a country within the European Union	 	$[*]
	 	Net Sales collectively exceed $25,000,000.00	 	$[*]
	 	Net Sales collectively exceed $50,000,000.00	 	$[*]
	 	Net Sales collectively exceed $100,000,000.00	 	$[*]

 

 

 

[*] Confidential treatment requested; certain information omitted
and filed separately with the SEC.

    10

     

    

 

Licensee shall
notify MD Anderson in writing immediately upon achievement of any of the foregoing milestones. Each of the foregoing milestone
payments shall be made by Licensee to MD Anderson (without invoice) within forty-five (45) calendar days of achieving the milestone
event and shall not reduce the amount of any other payment provided for in this Article IV. Notwithstanding anything to the contrary,
each milestone payment is payable only once under this Agreement, with respect to the initial accomplishment thereof, regardless
of the number of Licensed Products or the number of times such milestone may be achieved; and

 

		(g)	a payment of $[*] upon the first three (3) Change of Control events effected after the Effective
Date and upon each and every Assignment (“Transaction Value Payout”). Such payment shall be due and payable within
forty-five (45) days following the closing of such Change of Control.

 

		4.2	Unless otherwise provided, all such payments are payable within one hundred and five (105) calendar
days or contemporaneously with submission of information relating thereto to the Securities Exchange Commission (whichever is earlier)
after March 31, June 30, September 30, and December 31 of each year during the term of this Agreement, at which time after first
Sale Licensee will also deliver to MD Anderson a true and accurate report, giving such particulars of the business conducted during
the preceding three (3) calendar months under this Agreement as necessary for MD Anderson to account for Licensee’s payments hereunder.
This report will include pertinent data, including, but not limited to each of the following:

 

		(a)	The accounting methodologies used to account for and calculate the items included in the report
and any differences in such accounting methodologies used by Licensee since the previous report;

		(b)	A list of Licensed Products produced or provided for the three (3) preceding calendar months;

		(c)	The total quantities of Licensed Products produced or provided;

		(d)	The total Sales;

		(e)	The calculation of Net Sales;

		(f)	The royalties so computed and due MD Anderson by the Royalty Rate on Net Sales listed in Table
4.1(d) and/or Minimum Annual Royalties; and

		(g)	All other amounts due MD Anderson herein.

 

 

 

[*] Confidential treatment requested; certain information omitted
and filed separately with the SEC.

    11

     

    

 

Simultaneously with the delivery
of each such report, Licensee agrees to pay MD Anderson the amount due, if any, for the period of such report. These reports are
required even if no payments are due.

 

		4.3	For as long as Licensed Products are being sold or distributed and for one (1) year thereafter,
Licensee agrees to keep complete and accurate records of its Sales and Net Sales in sufficient detail to enable the royalties and
other payments due hereunder to be determined. Licensee agrees to permit a mutually agreeable, nationally recognized independent
accounting firm who has signed a non-disclosure agreement reasonably acceptable to Licensee, at MD Anderson’s expense, to examine
only those of Licensee’s books, ledgers, and records hereunder at a mutually agreed upon time during regular business hours,
but no more than once per calendar year and only after MD Anderson has provided Licensee with 30 days’ prior written notice,
for the purpose of and to the extent necessary to verify the accuracy of royalty payments, other payments, and reports required
pursuant to Section 4.2. All written reports, summaries thereof, and any correspondence related to any such audit shall be Confidential
Information of Licensee. If any amounts due MD Anderson are determined to have been underpaid in an amount equal to or greater
than five percent (5%) of the total amount due during the period so examined, then Licensee will pay the reasonable, documented
out-of-pocket cost paid by MD Anderson for the examination. Licensee shall pay accrued interest at 1% per month on any and all
late payments under this Agreement (regardless of whether the deficiency is identified by audit or otherwise), with such interest
commencing on the date after the due date.

 

		4.4	All amounts payable hereunder by Licensee shall be made in United States Dollar denominated funds,
free and clear and without any deduction, set-off, or reduction for or on account of any tax, levy, impost, duty, charge, fee or
withholding of any nature now or hereafter imposed by any governmental, fiscal or other authority.

 

Payments shall
be by checks made payable to The University of Texas M. D. Anderson Cancer Center, and sent by United States mail to Box 4390,
Houston, Texas 77210-4390, or by wire transfer to:

 

[*]

SWIFT: [*]

ABA ROUTING NO: [*] (wire)

ABA ROUTING NO: [*] (ACH)

ACCOUNT NAME: [*]

ACCOUNT NO.: [*]

REFERENCE: include title and
Effective Date of Agreement and type of payment (e.g., license upfront fee, milestone payment, royalty, maintenance fee, etc.)
and list applicable patent/application identified by MD Anderson reference number and patent number or application serial number.

 

 

 

[*] Confidential treatment requested; certain information omitted
and filed separately with the SEC.

    12

     

    

 

		4.5	No payments due or royalty rates owed under this Agreement will be reduced as the result of co-ownership
of Licensed Subject Matter by Board and another party, including, but not limited to, Licensee.

 

		4.6	If payment requires delivery of an invoice, then MD Anderson’s delay in providing an invoice
shall not excuse or waive any payment obligation of Licensee, but the deadline for Licensee’s payment shall be extended by
the period of such delay. An invoice shall be deemed to be delivered to Licensee if transmitted to Licensee’s address in
Section 14.2. Any failure by Licensee to update its billing address shall not excuse timely payment.

 

V. Patents
and Inventions

 

		5.1	MD Anderson shall be responsible for filing, prosecution and maintenance of patent applications
and patents within the Patent Rights. MD Anderson shall instruct such patent counsel to furnish Licensee with copies of all substantive
correspondence with patent offices, and shall give Licensee the opportunity to provide comments on and make requests of MD Anderson
concerning the filing, prosecution and maintenance of the Patent Rights, which comments and requests shall not be unreasonably
refused. If both parties agree that a new patent application should be filed for Licensed Subject Matter, MD Anderson will prepare
and file each such appropriate patent application, and Licensee will pay the related Patent Expenses. If Licensee notifies MD Anderson
in writing that it does not intend to pay for the preparation, filing, prosecution, or maintenance of any patent or patent application
within the Patent Rights (“Abandoned Patent Rights”), then MD Anderson may, in its sole discretion, elect to
file, not file, continue prosecution or maintenance, or abandon such patent application or patent at its own expense and shall
notify Licensee of its decision.  Licensee’s rights and obligations in any Abandoned Patent Rights shall terminate immediately
upon MD Anderson’s notification to Licensee of such election, but Licensee’s rights in all other Patent Rights shall
remain unaffected. System, Board, or MD Anderson shall provide written notice (“Abandonment Notice”) to Licensee prior
to abandoning prosecution or maintenance of any patent or patent application included in the Patent Rights. MD Anderson may not
abandon any such Patent Right without express written consent of Licensee, such consent must be provided within ten (10) days.
Notwithstanding the foregoing, MD Anderson may abandon such Patent Rights if Licensee (a) is delinquent in its payment by thirty
(30) or more days with respect to any invoiced Patent Expenses or other invoiced payment obligation hereunder and (b) has not cured
such delinquency after within thirty (30) calendar days after receiving written notice pursuant to Section 14.2 from MD Anderson
of such delinquency.

 

		5.2	Licensee shall reasonably cooperate with MD Anderson regarding all patent prosecution deadlines,
including without limitation any deadlines imposed by the Bayh-Dole Act or modifications or amendments thereto.

 

    13

     

    

 

		5.3	The parties agree that they share a common legal interest to get valid, enforceable patents and
that Licensee will keep all privileged information received pursuant to this Section confidential.

 

		5.4	If Licensee is delinquent with respect to any invoiced Patent Expenses or other invoiced payment
obligation hereunder and has not cured such delinquency after within thirty (30) calendar days after receiving written notice pursuant
to Section 14.2 from MD Anderson of such delinquency, then Board, MD Anderson, and the counsel prosecuting licensed patents and
patent applications shall have no obligation to confer or otherwise communicate with, or provide any information to, Licensee under
this Article V of this Agreement unless and until Licensee is no longer in arrears on all payments and obligations under this Agreement.

 

VI. Infringement
by Third Parties

 

		6.1	Licensee shall have the exclusive first and primary right, but
                                                                                                                   not the obligation, to institute, prosecute, and control any action or proceeding with respect to the infringement of any
                                                                                                                   patent exclusively licensed hereunder by third parties in the Licensed Field within the Licensed Territory, with mutually
                                                                                                                   agreeable counsel on any matter where such counsel represents Board or MD Anderson, and Licensee and such counsel agree to
                                                                                                                   follow all required procedures of the Texas Attorney General regarding retention of outside counsel for state entities.
                                                                                                                   Licensee shall be free to enter into a settlement, consent judgment, or other voluntary disposition with respect to any such
                                                                                                                   action, provided that any settlement, consent judgment or other voluntary disposition thereof shall be subject to approval by
                                                                                                                   Board and/or MD Anderson, if so required under any policy, rule or regulation of MD Anderson and/or Board, or any law of the
                                                                                                                   State of Texas, which approval shall not be unreasonably withheld or explicitly rejected, with any such rejection to be
                                                                                                                   accompanied by a reasonably detailed explanation for such rejection. In the event approval by Board is required, MD
                                                                                                                   Anderson’s Office of Technology Commercialization shall endeavor to obtain such approval consistent with Board’s
                                                                                                                   requirements and practices. Any recovery for actual damages or punitive or enhanced damages shall first be reimbursed to
                                                                                                                   Licensee for its documented, third-party expenses in enforcing the Patent Rights and amounts actually reimbursed by
                                                                                                                   Licensee to MD Anderson under this Section 6.1; any amounts in excess thereof shall be shared by Licensee with MD Anderson as
                                                                                                                   follows: [*]% of such recovery shall be provided to MD Anderson and [*]% shall be retained by Licensee. Licensee must notify
                                                                                                                   MD Anderson in writing of any potential infringement in the Licensed Field within the Licensed Territory within thirty (30)
                                                                                                                   calendar days of knowledge thereof. MD Anderson agrees to its normal and customary efforts to monitor for any potential
                                                                                                                   infringement in the Licensed Field within the Licensed Territory, and MD Anderson must notify Licensee in writing of any
                                                                                                                   potential infringement in the Licensed Field within the Licensed Territory within thirty (30) calendar days of the MD
                                                                                                                   Anderson Office of Technology Commercialization’s knowledge thereof.
If Licensee does not file suit against a substantial infringer in the Licensed Field within the Licensed Territory within six (6)
months of Licensee’s knowledge thereof, then Board or MD Anderson may, at its sole discretion upon sixty (60) calendar days’
notice, enforce any patent licensed hereunder on behalf of itself and Licensee, with MD Anderson retaining all recoveries from
such enforcement; provided, however, that MD Anderson shall first consult with Licensee and shall not initiate a suit or other
action if Licensee reasonably believes there is significant risk that such suit or action would jeopardize its rights under the
Agreement.

 

 

 

[*] Confidential treatment requested; certain information omitted
and filed separately with the SEC.

    14

     

    

 

VII. Patent
Marking

 

		7.1	Licensee agrees that all packaging containing individual Licensed Product(s), documentation therefor,
and, when possible, actual Licensed Product(s) sold by Licensee will be appropriately marked with the number of any applicable
patent(s) licensed hereunder in accordance with each country’s patent laws, including Title 35, United States Code, to the extent
such marking is necessary or required to fully preserve Patent Rights in each such country or the right to recover damages for
infringement thereof.

 

VIII. Indemnification
and Insurance

 

		8.1	LICENSEE AGREES TO HOLD HARMLESS AND INDEMNIFY BOARD, SYSTEM, MD ANDERSON, THEIR REGENTS, OFFICERS,
EMPLOYEES, STUDENTS AND AGENTS (THE “UT INDEMNITEES”) FROM AND AGAINST ANY THIRD-PARTY CLAIMS, DEMANDS, OR CAUSES OF
ACTION WHATSOEVER, COSTS OF SUIT AND REASONABLE ATTORNEY’S FEES (INCLUDING WITHOUT LIMITATION, THOSE COSTS ARISING ON ACCOUNT
OF ANY INJURY OR DEATH OF PERSONS OR DAMAGE TO PROPERTY) CAUSED BY, OR ARISING OUT OF, OR RESULTING FROM, THE EXERCISE OR PRACTICE
BY LICENSEE, ITS OFFICERS, ITS AFFILIATES OR THEIR OFFICERS, EMPLOYEES, AGENTS OR REPRESENTATIVES OF THE RIGHTS GRANTED HEREUNDER,
EXCEPT TO THE EXTENT CAUSED BY (1) ANY GROSS NEGLIGENCE OR WILLFUL MISCONDUCT ON THE PART OF ANY UT INDEMNITEE, (2) ANY BREACH
OF THIS AGREEMENT BY BOARD OR MD ANDERSON, OR (3) ANY VIOLATION OF LAW BY BOARD OR MD ANDERSON.

 

		8.2	IN NO EVENT SHALL LICENSEE, BOARD, SYSTEM, OR MD ANDERSON BE LIABLE FOR ANY INDIRECT, SPECIAL,
CONSEQUENTIAL OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR EXPECTED SAVINGS OR OTHER ECONOMIC
LOSSES, OR FOR INJURY TO PERSONS OR PROPERTY) ARISING OUT OF, OR IN CONNECTION WITH, THIS AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS
OF WHETHER BOARD, SYSTEM OR MD ANDERSON KNOWS OR SHOULD KNOW OF THE POSSIBILITY OF SUCH DAMAGES.

 

    15

     

    

 

		8.3	LICENSEE’S OBLIGATIONS TO HOLD HARMLESS AND INDEMNIFY THE UT INDEMNITEES IN SECTION 8.1 AND
THE LIMITATION OF LIABILITY IN SECTION 8.2 SHALL INCLUDE, BUT ARE NOT LIMITED TO, ANY CLAIM ALLEGING STRICT STATUTORY LIABILITY,
OR PRODUCT DEFECT LIABILITY THAT ARISES OUT OF, RELATES TO, IS CAUSED IN WHOLE OR IN PART BY, OR RESULTS FROM THE USE OR SALE OF
ANY TANGIBLE MATERIALS (INCLUDING BIOLOGICAL MATERIALS) PROVIDED TO LICENSEE BY BOARD OR MD ANDERSON UNDER OR IN CONNECTION WITH
THIS AGREEMENT OR PRODUCTS USED OR SOLD BY LICENSEE.

 

		8.4	Beginning at the time when any Licensed Subject Matter or any Licensed Product is being distributed
or sold (including for the purpose of obtaining regulatory approvals) by Licensee or its Affiliate(s), Licensee shall, at its sole
cost and expense, procure and maintain commercial general liability insurance in commercially reasonable and appropriate amounts
with respect to Licensed Products being Sold, and Licensee shall use reasonable efforts to have the Board, System, MD Anderson,
their Regents, officers, employees, students and agents named as additional insureds. Such commercial general liability insurance
shall provide: (i) product liability coverage; (ii) broad form contractual liability coverage for Licensee’s indemnification under
this Agreement; and (iii) coverage for litigation costs. The minimum amounts of insurance coverage required herein shall not be
construed to create a limit of Licensee’s liability with respect to its indemnification under this Agreement.

 

		8.5	Licensee shall provide MD Anderson with written evidence of such insurance within thirty (30) calendar
days of its procurement. Additionally, Licensee shall provide MD Anderson with written notice of at least fifteen (15) calendar
days prior to the cancellation, non-renewal or material change in such insurance.

 

		8.6	Licensee shall maintain such commercial general liability insurance beyond the expiration or termination
of this Agreement during: (i) the period that any Licensed Subject Matter developed pursuant to this Agreement is being commercially
distributed or sold by Licensee, its Affiliate(s), or agent(s) of Licensee; and (ii) the five (5) year period immediately after
such period.

 

    16

     

    

 

 IX. Use of Name

 

		9.1	Licensee will not use the name of (or the name of any employee of) MD Anderson, System or Board
in any advertising, promotional or sales literature, on its Web site, or for the purpose of raising capital without the advance
written consent of Board secured through:

 

The University of Texas

M. D. Anderson Cancer Center

Legal Services, Unit 1674

P.O. Box 301407

Houston, TX 77230-1407

 

Notwithstanding the above, Licensee
may use the name of (or name of employee of) MD Anderson, System, or Board in routine business correspondence, or as needed in
appropriate regulatory submissions without written consent.

 

		9.2	Neither Board, System, nor MD Anderson may use the name of Licensee (or the name of any Affiliate
or employee thereof) in any advertising, promotional or sales literature, or on its Web site, or for the purpose of raising capital
without the advance written consent of Licensee.

 

Notwithstanding the above, Board,
System, and MD Anderson may use the name of (or name of employee of) Licensee, in routine business correspondence, or as needed
in appropriate regulatory submissions without written consent.

 

 X. Confidential Information and Publication

 

		10.1	MD Anderson and Licensee each agree that all information disclosed by one party to the other party
in connection with this Agreement (“Confidential Information”): (i) is to be received in strict confidence,
(ii) is to be used only for the purposes of this Agreement, and (iii) will not be disclosed by the recipient party, its agents
or employees without the prior written consent of the disclosing party, except to the extent that the recipient party can establish
by competent written proof that such information:

 

	 	(a)	was in the public domain at the time of disclosure;

 

		(b)	later became part of the public domain through no act or omission of the recipient party, its employees,
agents, successors or assigns;

 

		(c)	was lawfully disclosed to the recipient party without obligation of confidentiality or limitation
on use by a third party who had the lawful right to disclose such information and who did not obtain such information under an
obligation of confidentiality to either party;

 

		(d)	was already in the possession of the recipient party at the time of disclosure to recipient; or

 

		(e)	was independently developed by the recipient party without the knowledge, use, or benefit of the
disclosing party’s confidential information.

 

Notwithstanding the foregoing,
all reports provided by Licensee and all information accessed or learned in connection with audits conducted under this Agreement
shall be deemed Licensee’s Confidential Information.

 

    17

     

    

 

		10.2	Each party’s obligation of confidence hereunder will be fulfilled by using at least the same
degree of care with the disclosing party’s Confidential Information as it uses to protect its own Confidential Information, but
always at least a reasonable degree of care. This obligation will exist while this Agreement is in force and for a period of three
(3) years thereafter.

 

		10.3	MD Anderson reserves the right to publish the general scientific findings from its research related
to Licensed Subject Matter, provided that it does not disclose Licensee’s Confidential Information. MD Anderson will submit
the manuscript of any such proposed publication to Licensee at least thirty (30) calendar days before publication, and Licensee
shall have the right to review and comment upon the publication in order to protect Licensee’s Confidential Information.
MD Anderson will incorporate Licensee’s reasonable comments in the proposed publications, provided such modifications do
not materially change the scientific content or conclusions. Upon Licensee’s request, publication may be delayed up to sixty
(60) additional calendar days to enable Licensee to secure adequate intellectual property protection of Licensee’s Confidential
Information that would otherwise be affected by the publication. Notwithstanding the foregoing, nothing in this Agreement shall
require MD Anderson or Board to refrain from publishing any information if doing so would (a) cause MD Anderson or Board to violate
any export control laws or laws that provide tax-exempt status for any bonds issued by MD Anderson or The University of Texas System,
or (b) result in the inapplicability to MD Anderson or The University of Texas System of the fundamental research exclusion or
exemption from U.S. export control laws for such information.

 

		10.4	In the event that the recipient party is required to disclose the disclosing party’s Confidential
Information under operation of applicable law, regulation, or order of a court or governmental administrative body having competent
jurisdiction, the recipient party shall, to the extent practicable, provide the disclosing party reasonable notice of such potential
disclosure so that that the disclosing party may seek a protective order or other appropriate protection or legal relief to prevent
or limit such disclosure. If, in the absence of, or pursuant to the terms of, such protection or legal relief, the recipient party
is nonetheless required by applicable law, regulation, or order of a court or governmental administrative body having competent
jurisdiction to disclose any portion of the disclosing party’s Confidential Information, the required disclosure shall be
permitted under this Agreement but shall be limited to only that portion of the disclosing party’s Confidential Information
for which disclosure is so required.

 

		10.5	The parties shall not make any public disclosure regarding this Agreement, except (a) if such disclosure
has been expressly approved by the other Party (such approval not to be unreasonably withheld, conditioned or delayed), or (b)
if advised by counsel to issue such disclosure in order to comply with applicable laws or a similar regulatory agency in another
applicable country or of any stock exchange of other securities trading institution.

 

    18

     

    

 

XI. Assignment

 

		11.1	This Agreement may not be assigned by Licensee, whether by assignment, by merger, by operation
of law, or by any other transfer, without the prior written consent of MD Anderson; provided, however, Licensee may assign
this Agreement without such consent (A) to any Affiliate of Licensee, or (B) in connection with a Change of Control.  For
any assignment (including without limitation, an assignment from the Licensee to one of its Affiliates) to be effective: (a) other
than solely with respect to an assignment from Licensee to an Affiliate, the Licensee must timely pay MD Anderson the Transaction
Value Payout specified in Section 4.1, unless waived by MD Anderson, in its sole discretion; and (b) the assignee (including any
Affiliate of Licensee) must assume in writing (a copy of which writing will be provided to MD Anderson) all of Licensee’s interests,
rights, duties, and obligations under the Agreement and agree to comply with all terms and conditions of the Agreement as if the
assignee were the original party (i.e., the Licensee) to the Agreement. Notwithstanding such assignment, with respect to an assignment
by Licensee to one of its Affiliates, the original Licensee (together with any Affiliate to which this Agreement is assigned)
shall remain responsible and liable for all of the “Licensee’s” responsibilities and liabilities under this Agreement. 
For the avoidance of doubt, if this Agreement is assigned to one of Licensee’s Affiliates in accordance with this Section 11.1,
such Affiliate shall also be deemed to be a “Licensee” under this Agreement, and such Affiliate of Licensee shall also
be liable for all responsibilities, obligations, and liabilities of Licensee under this Agreement.

 

		11.2	Any attempt to assign this Agreement by Licensee in violation of Section 11.1 is null and void
without MD Anderson’s prior written consent.

 

XII. Term
and Termination

 

		12.1	Subject to Sections 12.3 and 12.4 hereinbelow, the term of this Agreement is from the Effective
Date until the last to occur of: (a) the expiration of all patents issued under Patent Rights (if any) and the cancellation, withdrawal,
or express abandonment of all patent applications under Patents Rights (if any), or (b) the date that is the fifteenth (15th)
anniversary of the Effective Date.

 

		12.2	Any time after four (4) years from the Effective Date, Board or MD Anderson has the right to eliminate
any country or jurisdiction from the Licensed Territory if Licensee, within ninety (90) calendar days after receiving written notice
from MD Anderson of the intended termination, fails to provide written evidence satisfactory to MD Anderson that Licensee has commercialized
or is actively and effectively attempting to commercialize a licensed invention in such country or jurisdiction. The following
definitions apply to Section 12.2: (a) “commercialized” means having Sales in such jurisdiction; and (b) “actively
and effectively attempting to commercialize” means having an effective, ongoing and active research, development, manufacturing,
marketing or sales program as appropriate, directed toward obtaining regulatory approval, and/or production and/or Sales in any
jurisdiction, and providing plans acceptable to MD Anderson, in its sole discretion, to commercialize licensed inventions in the
jurisdiction(s) in which MD Anderson intends to terminate.

 

    19

     

    

 

		12.3	Subject to any rights herein which survive termination, this Agreement will earlier terminate in
its entirety:

 

		(a)	Subject to Section 12.3(f), upon thirty (30) calendar days written notice from MD Anderson, if
Licensee breaches or defaults on the payment or report obligations of Article IV (excluding the license documentation fee specified
in Section 4.1(b), for which no cure period applies), unless, before the end of such thirty (30)-calendar day notice period (“Notice
Period”), Licensee has cured the default or breach, and so notifies MD Anderson, stating the manner of the cure, provided
however any cure of breach of use of name obligations of Article IX shall be to MD Anderson’s satisfaction; provided further
that the parties agree that breach or default on a payment obligation (other than failure to pay the license documentation fee
specified in Section 4.1(b)), is cured by Licensee’s payment within the Notice Period of past due amounts related to such
breach or default;

 

		(b)	immediately, upon written notice from MD Anderson, if Licensee fails to timely pay the license
upfront fee specified in Section 4.1(b);

 

		(c)	upon ninety (90) calendar days written notice from MD Anderson if Licensee materially breaches
or defaults on any other obligation under this Agreement, unless, before the end of such ninety (90) calendar-day notice period,
Licensee has cured the default or breach and so notifies MD Anderson, stating the manner of the cure;

 

		(d)	at any time by mutual written agreement between Licensee and MD Anderson upon one hundred eighty
(180) calendar days written notice to all parties and subject to any terms herein which survive termination;

 

		(e)	In the event that Licensee (or its Affiliate) brings an action, or participates as an adverse party
in any action, before any court, agency or tribunal seeking to invalidate or otherwise challenge the enforceability of or Board’s
ownership of any patent included in the Patent Rights, then MD Anderson may immediately terminate this Agreement upon written notice
to Licensee and with no opportunity for Licensee to cure. Any dispute regarding the validity, enforceability or ownership of any
patent included in the Patent Rights shall be litigated in the courts located in Houston, Texas, and Licensee agrees not to challenge
personal jurisdiction in that forum. To the extent that Licensee unsuccessfully challenges, or participates as an adverse party
in an action that unsuccessfully challenges, the validity or enforceability of any patent included in the Patent Rights, Licensee
agrees to reimburse MD Anderson and Board for all costs and fees (including attorney’s fees) paid by MD Anderson and Board
in defending against such challenge. Licensee understands and agrees that, in the event Licensee successfully challenges the validity
or enforceability of any patent included in the Patent Rights, all payments or other consideration made or otherwise provided by
Licensee to MD Anderson prior to a final, non-appealable adjudication of invalidity and/or unenforceability shall be non-refundable.
The obligations of this Section shall survive the expiration or termination of this Agreement;

 

    20

     

    

 

		(f)	notwithstanding Section 12.3(a), upon thirty (30) calendar days written notice from MD Anderson
if Licensee has defaulted or been late on its undisputed payment obligations pursuant to the terms of this Agreement on any two
(2) occasions in a twenty-four (24) month period and subsequently fails to make an undisputed payment obligation more than fifteen
(15) calendar after receiving notice from MD Anderson regarding such failure; or

 

		(g)	upon one hundred eighty (180) calendar days written notice from Licensee to MD Anderson.

 

	 	12.4	Upon termination of this Agreement:

 

		(a)	nothing herein will be construed to release either party of any obligation maturing prior to the
effective date of the termination;

 

		(b)	Licensee covenants and agrees to remain bound by the provisions of Articles VIII (Indemnification
and Insurance), IX (Use of Board and MD Anderson’s Name) and X (Confidential Information and Publication) of this Agreement;
and

 

		(c)	Licensee agrees to cease and desist any use and all Sales of the Licensed Subject Matter and Licensed
Products upon termination of this Agreement; provided, however, Licensee and its Affiliates shall have the right, subject to Licensee’s
payment of royalties as required under Article 4, to Sell any finished Licensed Products or Licensed Products in inventory or in
the process of manufacture as of the date this Agreement is terminated (the “Termination Date”) for the twelve
month period beginning on the Termination Date (“Sell-Down Period”). The reporting and audit provisions of Article
4 shall apply to any Sales of Licensed Products made during such Sell-Down Period.

 

    21

     

    

 

XIII. Warranty:
Superior-Rights

 

		13.1	Except for the rights, if any, of the Government of the United States of America (“Government”)
as set forth below, Board represents and warrants that, to the knowledge of the MD Anderson Office of Technology Commercialization,
(a) Board is the sole owner of the entire right, title, and interest in and to Licensed Subject Matter, (b) Board has the right,
power, and authority to grant licenses thereunder, (c) Board has not knowingly granted licenses thereunder to any other entity
that would restrict rights granted hereunder except as stated herein, and (d) neither the execution of this Agreement nor the performance
of Board’s or MD Anderson’s obligations hereunder will constitute a breach under the terms and provisions of any other
agreement to which MD Anderson or Board is a party.

 

		13.2	Licensee understands that the Licensed Subject Matter may have been developed under a funding agreement
with the Government and, if so, that the Government may have certain rights relative thereto. This Agreement is explicitly made
subject to the Government’s rights under any such agreement and any applicable law or regulation. To the extent that there is a
conflict between any such agreement, applicable law or regulation and this Agreement, the terms of such Government agreement, applicable
law or regulation shall prevail. Licensee agrees that Licensed Products used or Sold in the United States will be manufactured
substantially in the United States, unless a written waiver is obtained in advance from the Government.

 

		13.3	LICENSEE UNDERSTANDS AND AGREES THAT BOARD AND MD ANDERSON, BY THIS AGREEMENT, MAKE NO REPRESENTATION
AS TO THE OPERABILITY OR FITNESS FOR ANY USE, SAFETY, EFFICACY, APPROVABILITY BY REGULATORY AUTHORITIES, TIME AND COST OF DEVELOPMENT,
PATENTABILITY, AND/OR BREADTH OF THE LICENSED SUBJECT MATTER. BOARD AND MD ANDERSON, BY THIS AGREEMENT, ALSO MAKE NO REPRESENTATION
AS TO WHETHER ANY PATENT COVERED BY PATENT RIGHTS IS VALID OR AS TO WHETHER THERE ARE ANY PATENTS NOW HELD, OR WHICH WILL BE HELD,
BY OTHERS OR BY BOARD OR MD ANDERSON IN THE LICENSED FIELD, NOR DO BOARD AND MD ANDERSON MAKE ANY REPRESENTATION THAT THE INVENTIONS
CONTAINED IN PATENT RIGHTS DO NOT INFRINGE ANY OTHER PATENTS NOW HELD OR THAT WILL BE HELD BY OTHERS OR BY BOARD.

 

		13.4	Licensee, by execution hereof, acknowledges, covenants and agrees that Licensee has not been induced
in any way by Board, System, MD Anderson or employees thereof to enter into this Agreement, and further warrants and represents
that (a) Licensee is entering into this Agreement voluntarily; (b) Licensee has conducted sufficient due diligence with respect
to all items and issues pertaining to this Agreement; and (c) Licensee has adequate knowledge and expertise, or has used knowledgeable
and expert consultants, to adequately conduct such due diligence, and agrees to accept all risks inherent herein.

 

    22

     

    

 

XIV. General

 

		14.1	This Agreement, and all claims arising out of or relating thereto, together with any exhibits and/or
fully executed amendments hereto, constitutes the entire and only agreement between the parties for Licensed Subject Matter and
all other prior negotiations, representations, agreements and understandings related to the subject matter of this Agreement are
superseded hereby. Neither party has relied on any such prior communication in entering into this Agreement. No agreements altering
or supplementing the terms hereof will be made except by a written document signed by both parties.

 

		14.2	Any notice required by this Agreement shall be in writing and shall be deemed to have been sufficiently
given for all purposes thereof when sent by first class mail or reputable international courier (e.g., Federal Express or UPS)
and shall be evidenced by the postmark at the point of mailing or by the dated delivery receipt of the courier. All notices and
any correspondence respecting this Agreement shall be transmitted as follows:

 

To MD Anderson, if by mail:

The University of Texas M. D. Anderson Cancer
Center

Strategic Industry Ventures/Office of Technology
Commercialization

Unit 1669

P.O. Box 301407

Houston, Texas 77230-1407

 

To MD Anderson, if by courier:

The University of Texas M. D. Anderson Cancer
Center

Strategic Industry Ventures/Office of Technology
Commercialization

1MC9.2216

7007 Bertner Avenue

Houston, Texas 77030-3907

 

To Licensee by mail or courier:

Citius Pharmaceuticals, Inc.

11 Commerce Drive, First Floor

Cranford, NJ 07016

Attn: Myron Holubiak, CEO

 

or other addresses as may be
given from time to time under the terms of this notice provision.

 

Communications
regarding patent prosecution may be transmitted by electronic mail.  For such communications to MD Anderson sent via electronic
mail, the electronic mail shall be addressed or copied to patentmail@mdanderson.org. 

 

		14.3	Licensee must comply with all applicable federal, state and local laws and regulations in connection
with its activities pursuant to this Agreement or Licensed Subject Matter, including U.S. Export Administration Regulations, as
well as end-user, end-use, and destination restrictions applied by the United States. Licensee acknowledges that the Licensed Subject
Matter is subject to U.S. export control jurisdiction.

 

    23

     

    

 

		14.4	This Agreement and all claims arising out of or relating thereto will be governed, construed and
enforced in accordance with the laws of the United States of America and of the State of Texas, without regard to its conflict
of law provisions. The Texas State Courts of Harris County, Texas (or, if there is exclusive federal jurisdiction, the United States
District Court for the Southern District of Texas) shall have exclusive jurisdiction and venue over any dispute arising out of
this Agreement, and Licensee consents to the jurisdiction and venue of such courts and hereby explicitly waives the rights to any
other venue to which it might be entitled by cause of action, domicile or otherwise.

 

		14.5	Notwithstanding the foregoing, to the extent that Chapter 2260, Texas Government Code, as it may
be amended from time to time (“Chapter 2260”), is applicable to this Agreement, Licensee acknowledges and agrees that
the dispute resolution process provided for in Chapter 2260 shall be Licensee’s sole and exclusive process for seeking a
remedy for any and all alleged breaches of the Agreement by Board and/or MD Anderson or the State of Texas.

 

		14.6	Failure any party to enforce a right under this Agreement will not act as a waiver of right or
the ability to later assert that right relative to the particular situation involved.

 

		14.7	Headings included herein are for convenience only and will not be used to construe this Agreement.
The Parties acknowledge and agree that both Parties substantially participated in negotiating the provisions of this Agreement;
therefore, both Parties agree that any ambiguity in this Agreement shall not be construed more favorably toward one Party than
the other Party, regardless of which Party primarily drafted this Agreement.

 

		14.8	If any provision of this Agreement is for any reason found to be invalid or unenforceable, such
provision shall be interpreted to fulfill its intended purpose to the maximum extent permitted by applicable law and all other
provisions of this Agreement nevertheless will remain enforceable.

 

		14.9	If Licensee desires to sponsor research for or related to the Licensed Subject Matter, Licensee
(a) will notify MD Anderson in writing of all opportunities to conduct this sponsored research (including clinical trials, if applicable),
(b) will solicit research and/or clinical proposals from MD Anderson for this purpose, and (c) will give good faith consideration
to funding the proposals at MD Anderson.

 

		14.10	This Agreement may be executed in one (1) or more counterparts, by original, facsimile or PDF signature,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Signatures
to this Agreement transmitted by facsimile, by email in “portable document format” (“.pdf”), or by any
other electronic means intended to preserve the original graphic and pictorial appearance of this Agreement shall have the same
effect as physical delivery of the paper document bearing original signature.  In the event signatures are exchanged by facsimile
and/or in “.pdf” format, each party shall thereafter promptly provide an original signature page to the other party.

 

		14.11	MD Anderson, as an agency of the State of Texas and a member institution of The University of Texas
System, is subject to the constitution and laws of the State of Texas and, under the constitution and laws of the State of Texas,
possesses certain rights and privileges, is subject to certain limitations and restrictions, and only has such authority as is
granted under the constitution and laws of the State of Texas. Notwithstanding anything to the contrary herein, nothing in this
Agreement shall obligate The University of Texas System, The Board of Regents of The University of Texas System, MD Anderson, or
any other agency of The State of Texas to join, or permit the use of its name or otherwise participate, as a litigant in any litigation
or adversarial judicial proceeding. Moreover, notwithstanding the generality or specificity of any provision of this Agreement,
the provisions of this Agreement as they pertain to MD Anderson are enforceable only to the extent authorized by the constitution
and laws of the State of Texas. No party to this Agreement will be required to perform or commit any act or omission that would
violate any applicable law, including the constitution and laws of the State of Texas. Nothing in this Agreement shall be deemed
as a waiver by Board, System or MD Anderson of its sovereign immunity.

 

 

[Signatures Appear on
Following Pages]

    24

     

    

 

IN WITNESS WHEREOF, the parties
hereto have caused their duly authorized representatives to execute this Agreement.

 

	BOARD OF REGENTS OF THE

UNIVERSITY OF TEXAS System, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER	 
	 	 
	By 	          	 

	
        Printed Name: 
	 	 

	
        Title:
	    	 

 

Date:_______________

 

	Approved as to Content:	 
	 	 
	By	 	 
	 	
        Ferran Prat, J.D., Ph.D.

        Senior Vice President

        Research Administration & Industry Relations

        M. D. Anderson Cancer Center
	 

 

Date:________________

 

Licensee: Citius Pharmaceuticals, Inc.

 

	By	    	 

	Printed Name: 	 	 

	Title:	    	 

 

Date: ________________

 

    25

     

    

 

EXHIBIT I

 

	MDA No. 	 	Creators (Include M.D.)	 	IDR Title 	 	All U.S. and foreign patent application/patent numbers (country code and serial number – only include pending or issued applications)
	MDA13-011	 	
        Issam Raad, MD

        Joel Rosenblatt, PhD

        Andrew Dennis, PhD

        George Viola, MD

        Jesse Selber, MD
	 	Method for Applying a Conformal Liquid Coating to an Implant	 	
        61/813,564 (US Prov.)

        PCT/US2014/034556 (PCT)

        9,849,217 (US Issued)

        15/820,154 (US Divisional)

 

 

i

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}]]